TP53 and cancer: A third hypothesis predicting a reduced excellent response (compared to H0), NED in final follow-up, tumor size ≤10 mm (compared with >10 mm and ≤20 mm), classic cancer subtype (compared with other aggressive tumors), absence of vascular invasion, and age <55 years in patients with higher CHK2 expression, TP53 gene copy deletion, and positive p53 together with a TP53 gene copy deletion was qualitatively consistent with the data.